Tech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on HitIQ.
RELATED STOCKHEAD STORIES
Health & Biotech
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
Health & Biotech
ASX Health Stocks: Amplia’s pancreatic cancer drug shows progress
Health & Biotech
ASX Health Stocks: CBL targets more reimbursement revenue for NeuroNode device
Health & Biotech
ASX Health Stocks: HITIQ secures US patent; BlinkLab joins forces in Europe to transform ADHD diagnosis
Health & Biotech
ASX Health Stocks: HitIQ’s mouthguard approved by World Rugby; Neurotech reports positive results
Health & Biotech
The next Neuren? Nyrada chases after two big markets – stroke and traumatic brain injury
Health & Biotech
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Health & Biotech
Diagnosing mental disorder through sleep: How TrivarX could capture this huge research market
News
Rise and Shine: Everything you need to know before the ASX opens
News
Top 10 at 10: Minnow soars to 80pc gain on AFL deal
News
In Case You Missed It: High grade gold for the win
Experts
CRITERION: Do these ASX plays of the day deserve a sporting chance?
Experts
How to play the blockbuster UFC-WWE merger, and why these sports stocks could also be good investments
Health & Biotech
ASX Health Stocks: Neuren surges 20pc on ‘historic’ FDA approval, HITIQ snaps up Monash Uni as customer
News
Market Highlights: Defiant Wall Street, Man U for sale, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: HITIQ signs two-year deal with UK Rugby Football League
IPO Watch
